Brief: Valneva, LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
09/04/2025 06:13
April 9 (Reuters) - Valneva SE VLS.PA: VALNEVA AND LIMMATECH ANNOUNCE FIRST VACCINATION IN PHASE 2 INFANT STUDY OF TETRAVALENT SHIGELLA VACCINE CANDIDATE S4V2 PHASE 2 STUDY TO TEST SAFETY AND IMMUNOGENICITY IN 110 INFANTS STUDY RESULTS EXPECTED IN SECOND HALF OF 2025 FIRST PARTICIPANT VACCINATED IN PHASE 2 STUDY OF SHIGELLA VACCINE FDA GRANTS FAST TRACK DESIGNATION TO S4V2 Source text: ID:nGNE3sNtyY Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency